�ݺ�ߣshows by User: DauRamChandravanshi1

�ݺ�ߣshows by User: DauRamChandravanshi1 / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: DauRamChandravanshi1 / Tue, 10 Dec 2024 05:34:42 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: DauRamChandravanshi1 Pharmaceutical Inorganic Chemistry: Unit-V Radiopharmaceuticals /slideshow/pharmaceutical-inorganic-chemistry-unit-v-radiopharmaceuticals/273954137 unit-vradiopharmaceuticals-241210053442-11920643
The theory of radioactive disintegration, proposed by Rutherford and Soddy in 1903, explained that radioactive elements emit α and β particles, forming new elements. In 1909, Rutherford and Royds identified α-particles as helium nuclei; in 1911, Rutherford proposed the nuclear theory of the atom based on α-particle scattering. Bohr later built upon this with his atomic structure theory in 1913. Rutherford, a pioneering nuclear scientist, observed elemental transmutation in 1919 but doubted nuclear power's feasibility, which was achieved five years later in 1942 by Fermi's nuclear reactor. Research on atomic nuclei has led to over 2,500 atom species, benefiting fields like industry, medicine, and agriculture. Radioactivity is a spontaneous, irreversible nuclear phenomenon causing elemental transformation. Marie Curie first used the term radioactivity. In 1896, Marie Curie systematically studied the substances emitting radioactive rays for her doctorate thesis. ]]>
The theory of radioactive disintegration, proposed by Rutherford and Soddy in 1903, explained that radioactive elements emit α and β particles, forming new elements. In 1909, Rutherford and Royds identified α-particles as helium nuclei; in 1911, Rutherford proposed the nuclear theory of the atom based on α-particle scattering. Bohr later built upon this with his atomic structure theory in 1913. Rutherford, a pioneering nuclear scientist, observed elemental transmutation in 1919 but doubted nuclear power's feasibility, which was achieved five years later in 1942 by Fermi's nuclear reactor. Research on atomic nuclei has led to over 2,500 atom species, benefiting fields like industry, medicine, and agriculture. Radioactivity is a spontaneous, irreversible nuclear phenomenon causing elemental transformation. Marie Curie first used the term radioactivity. In 1896, Marie Curie systematically studied the substances emitting radioactive rays for her doctorate thesis. ]]> Tue, 10 Dec 2024 05:34:42 GMT /slideshow/pharmaceutical-inorganic-chemistry-unit-v-radiopharmaceuticals/273954137 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Pharmaceutical Inorganic Chemistry: Unit-V Radiopharmaceuticals DauRamChandravanshi1 The theory of radioactive disintegration, proposed by Rutherford and Soddy in 1903, explained that radioactive elements emit α and β particles, forming new elements. In 1909, Rutherford and Royds identified α-particles as helium nuclei; in 1911, Rutherford proposed the nuclear theory of the atom based on α-particle scattering. Bohr later built upon this with his atomic structure theory in 1913. Rutherford, a pioneering nuclear scientist, observed elemental transmutation in 1919 but doubted nuclear power's feasibility, which was achieved five years later in 1942 by Fermi's nuclear reactor. Research on atomic nuclei has led to over 2,500 atom species, benefiting fields like industry, medicine, and agriculture. Radioactivity is a spontaneous, irreversible nuclear phenomenon causing elemental transformation. Marie Curie first used the term radioactivity. In 1896, Marie Curie systematically studied the substances emitting radioactive rays for her doctorate thesis. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/unit-vradiopharmaceuticals-241210053442-11920643-thumbnail.jpg?width=120&height=120&fit=bounds" /> The theory of radioactive disintegration, proposed by Rutherford and Soddy in 1903, explained that radioactive elements emit α and β particles, forming new elements. In 1909, Rutherford and Royds identified α-particles as helium nuclei; in 1911, Rutherford proposed the nuclear theory of the atom based on α-particle scattering. Bohr later built upon this with his atomic structure theory in 1913. Rutherford, a pioneering nuclear scientist, observed elemental transmutation in 1919 but doubted nuclear power's feasibility, which was achieved five years later in 1942 by Fermi's nuclear reactor. Research on atomic nuclei has led to over 2,500 atom species, benefiting fields like industry, medicine, and agriculture. Radioactivity is a spontaneous, irreversible nuclear phenomenon causing elemental transformation. Marie Curie first used the term radioactivity. In 1896, Marie Curie systematically studied the substances emitting radioactive rays for her doctorate thesis.

Pharmaceutical Inorganic Chemistry: Unit-V Radiopharmaceuticals from D.R. Chandravanshi

]]> 68 0 https://cdn.slidesharecdn.com/ss_thumbnails/unit-vradiopharmaceuticals-241210053442-11920643-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Pharma. Inorganic Chemistry. Gastrointestinal Agents /slideshow/pharma-inorganic-chemistry-gastrointestinal-agents-pptx/272564363 gastrointestinalagents-241020015158-93ac85e5
The digestive system is the gastrointestinal tract (GIT) It starts from the esophagus to the anus. The central portion of GIT includes the stomach, small intestine, large intestine, and the rectum with the exit anus. Whenever the functions of GIT go wrong, disease occurs. Disease of GIT: Inadequate secretion of acid in the stomach causes achlorhydria or hypochlorhydria. When excess of acid secretion takes place in stomach, this causes imbalance of acid – enzyme ratio, which causes hyperacidity or ulcer. There may occur accumulation of toxic substances or gases. There may occur inadequate absorption of fluids and minerals from large intestine, which causes diarrhoea. There may occur insufficient peristaltic movement of large intestine, thereby causing constipation. There may occur inadequate secretion of saliva, thereby making the food to swallow with difficulty. There may occur ingestion of poisonous substance accidentally or intentionally by some person. It is possible to correct the above conditions by administration of suitable drugs, which are called the GASTROINTESTINAL AGENTS.]]>
The digestive system is the gastrointestinal tract (GIT) It starts from the esophagus to the anus. The central portion of GIT includes the stomach, small intestine, large intestine, and the rectum with the exit anus. Whenever the functions of GIT go wrong, disease occurs. Disease of GIT: Inadequate secretion of acid in the stomach causes achlorhydria or hypochlorhydria. When excess of acid secretion takes place in stomach, this causes imbalance of acid – enzyme ratio, which causes hyperacidity or ulcer. There may occur accumulation of toxic substances or gases. There may occur inadequate absorption of fluids and minerals from large intestine, which causes diarrhoea. There may occur insufficient peristaltic movement of large intestine, thereby causing constipation. There may occur inadequate secretion of saliva, thereby making the food to swallow with difficulty. There may occur ingestion of poisonous substance accidentally or intentionally by some person. It is possible to correct the above conditions by administration of suitable drugs, which are called the GASTROINTESTINAL AGENTS.]]> Sun, 20 Oct 2024 01:51:57 GMT /slideshow/pharma-inorganic-chemistry-gastrointestinal-agents-pptx/272564363 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Pharma. Inorganic Chemistry. Gastrointestinal Agents DauRamChandravanshi1 The digestive system is the gastrointestinal tract (GIT) It starts from the esophagus to the anus. The central portion of GIT includes the stomach, small intestine, large intestine, and the rectum with the exit anus. Whenever the functions of GIT go wrong, disease occurs. Disease of GIT: Inadequate secretion of acid in the stomach causes achlorhydria or hypochlorhydria. When excess of acid secretion takes place in stomach, this causes imbalance of acid – enzyme ratio, which causes hyperacidity or ulcer. There may occur accumulation of toxic substances or gases. There may occur inadequate absorption of fluids and minerals from large intestine, which causes diarrhoea. There may occur insufficient peristaltic movement of large intestine, thereby causing constipation. There may occur inadequate secretion of saliva, thereby making the food to swallow with difficulty. There may occur ingestion of poisonous substance accidentally or intentionally by some person. It is possible to correct the above conditions by administration of suitable drugs, which are called the GASTROINTESTINAL AGENTS. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/gastrointestinalagents-241020015158-93ac85e5-thumbnail.jpg?width=120&height=120&fit=bounds" /> The digestive system is the gastrointestinal tract (GIT) It starts from the esophagus to the anus. The central portion of GIT includes the stomach, small intestine, large intestine, and the rectum with the exit anus. Whenever the functions of GIT go wrong, disease occurs. Disease of GIT: Inadequate secretion of acid in the stomach causes achlorhydria or hypochlorhydria. When excess of acid secretion takes place in stomach, this causes imbalance of acid – enzyme ratio, which causes hyperacidity or ulcer. There may occur accumulation of toxic substances or gases. There may occur inadequate absorption of fluids and minerals from large intestine, which causes diarrhoea. There may occur insufficient peristaltic movement of large intestine, thereby causing constipation. There may occur inadequate secretion of saliva, thereby making the food to swallow with difficulty. There may occur ingestion of poisonous substance accidentally or intentionally by some person. It is possible to correct the above conditions by administration of suitable drugs, which are called the GASTROINTESTINAL AGENTS.

Pharma. Inorganic Chemistry. Gastrointestinal Agents from D.R. Chandravanshi

]]> 617 0 https://cdn.slidesharecdn.com/ss_thumbnails/gastrointestinalagents-241020015158-93ac85e5-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Questions of Central Nervous System /slideshow/questions-of-central-nervous-system/257947387 classtest-230522021733-33fdd469
These are the possible questions that may ask in examination of human anatomy and physiology]]>
These are the possible questions that may ask in examination of human anatomy and physiology]]> Mon, 22 May 2023 02:17:33 GMT /slideshow/questions-of-central-nervous-system/257947387 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Questions of Central Nervous System DauRamChandravanshi1 These are the possible questions that may ask in examination of human anatomy and physiology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/classtest-230522021733-33fdd469-thumbnail.jpg?width=120&height=120&fit=bounds" /> These are the possible questions that may ask in examination of human anatomy and physiology

Questions of Central Nervous System from D.R. Chandravanshi

]]> 229 0 https://cdn.slidesharecdn.com/ss_thumbnails/classtest-230522021733-33fdd469-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Drug Store and Business Management (DSBM).pdf /slideshow/drug-store-and-business-management-dsbmpdf/254900596 drugstoreandbusinessmanagementdsbm-221214145818-3f2cacab
Human life is based upon the principle of work. ▪ One has to work to earn his livelihood. ▪ Pharmacy is one of the professions. ▪ The pharmacy council of India has introduced a new subject named “Drug store and business management”. ▪ Syllabus is divided into two parts – part I commerce and part II Accountancy. ▪ The purpose of this subject is to familiarise the students with the basic concept of business, its proper management, sources of finances in order to run it successfully and the last, the way and means to note down various transactions in books of account with a view to having a permanent record of the same.]]>
Human life is based upon the principle of work. ▪ One has to work to earn his livelihood. ▪ Pharmacy is one of the professions. ▪ The pharmacy council of India has introduced a new subject named “Drug store and business management”. ▪ Syllabus is divided into two parts – part I commerce and part II Accountancy. ▪ The purpose of this subject is to familiarise the students with the basic concept of business, its proper management, sources of finances in order to run it successfully and the last, the way and means to note down various transactions in books of account with a view to having a permanent record of the same.]]> Wed, 14 Dec 2022 14:58:17 GMT /slideshow/drug-store-and-business-management-dsbmpdf/254900596 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Drug Store and Business Management (DSBM).pdf DauRamChandravanshi1 Human life is based upon the principle of work. ▪ One has to work to earn his livelihood. ▪ Pharmacy is one of the professions. ▪ The pharmacy council of India has introduced a new subject named “Drug store and business management”. ▪ Syllabus is divided into two parts – part I commerce and part II Accountancy. ▪ The purpose of this subject is to familiarise the students with the basic concept of business, its proper management, sources of finances in order to run it successfully and the last, the way and means to note down various transactions in books of account with a view to having a permanent record of the same. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/drugstoreandbusinessmanagementdsbm-221214145818-3f2cacab-thumbnail.jpg?width=120&height=120&fit=bounds" /> Human life is based upon the principle of work. ▪ One has to work to earn his livelihood. ▪ Pharmacy is one of the professions. ▪ The pharmacy council of India has introduced a new subject named “Drug store and business management”. ▪ Syllabus is divided into two parts – part I commerce and part II Accountancy. ▪ The purpose of this subject is to familiarise the students with the basic concept of business, its proper management, sources of finances in order to run it successfully and the last, the way and means to note down various transactions in books of account with a view to having a permanent record of the same.

Drug Store and Business Management (DSBM).pdf from D.R. Chandravanshi

]]> 3535 0 https://cdn.slidesharecdn.com/ss_thumbnails/drugstoreandbusinessmanagementdsbm-221214145818-3f2cacab-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Channel of Distribution.pdf /slideshow/channel-of-distributionpdf/254900354 channelofdistribution-221214143120-b4f978a1
Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”]]>
Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”]]> Wed, 14 Dec 2022 14:31:20 GMT /slideshow/channel-of-distributionpdf/254900354 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Channel of Distribution.pdf DauRamChandravanshi1 Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution” <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/channelofdistribution-221214143120-b4f978a1-thumbnail.jpg?width=120&height=120&fit=bounds" /> Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”

Channel of Distribution.pdf from D.R. Chandravanshi

]]> 115 0 https://cdn.slidesharecdn.com/ss_thumbnails/channelofdistribution-221214143120-b4f978a1-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Channels of Distribution.pdf /slideshow/channels-of-distributionpdf/254900270 channelsofdistribution-221214142513-f7a1b818
Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”]]>
Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”]]> Wed, 14 Dec 2022 14:25:13 GMT /slideshow/channels-of-distributionpdf/254900270 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Channels of Distribution.pdf DauRamChandravanshi1 Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution” <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/channelsofdistribution-221214142513-f7a1b818-thumbnail.jpg?width=120&height=120&fit=bounds" /> Distribution is significant rated as a significant function of marketing. After production a product moves to the market and finally to the consumer. ▪ This journey of the product from the manufacturer or producer to the consumer is made possible through certain defined paths, termed as, “Channels of Distribution”

Channels of Distribution.pdf from D.R. Chandravanshi

]]> 1140 0 https://cdn.slidesharecdn.com/ss_thumbnails/channelsofdistribution-221214142513-f7a1b818-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Monoclonal Antibody Process.pdf /slideshow/monoclonal-antibody-processpdf/251820450 monoclonalab-220520073748-aca9db26
Monoclonal antibodies are antibodies that have a high degree of specificity (mono-specificity) for an antigen or epitope. Monoclonal antibodies are typically derived from a clonal expansion of antibody producing malignant human plasma cells. The initial monoclonal antibodies were created by fusing spleen cells from an immunized mouse with human or mouse myeloma cells (malignant self-perpetuating antibody producing cells), and selecting out and cloning the hybrid cells (hybridomas) that produced the desired antibody reactivity. These initial monoclonal products were mouse antibodies and were very valuable in laboratory and animal research and diagnostic assays, but were problematic as therapeutic agents because of immune reactions to the foreign mouse protein. Subsequently, production of chimeric mouse-human monoclonal antibodies and means of further “humanizing” them and producing fully human recombinant monoclonal antibodies were developed.]]>
Monoclonal antibodies are antibodies that have a high degree of specificity (mono-specificity) for an antigen or epitope. Monoclonal antibodies are typically derived from a clonal expansion of antibody producing malignant human plasma cells. The initial monoclonal antibodies were created by fusing spleen cells from an immunized mouse with human or mouse myeloma cells (malignant self-perpetuating antibody producing cells), and selecting out and cloning the hybrid cells (hybridomas) that produced the desired antibody reactivity. These initial monoclonal products were mouse antibodies and were very valuable in laboratory and animal research and diagnostic assays, but were problematic as therapeutic agents because of immune reactions to the foreign mouse protein. Subsequently, production of chimeric mouse-human monoclonal antibodies and means of further “humanizing” them and producing fully human recombinant monoclonal antibodies were developed.]]> Fri, 20 May 2022 07:37:48 GMT /slideshow/monoclonal-antibody-processpdf/251820450 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Monoclonal Antibody Process.pdf DauRamChandravanshi1 Monoclonal antibodies are antibodies that have a high degree of specificity (mono-specificity) for an antigen or epitope. Monoclonal antibodies are typically derived from a clonal expansion of antibody producing malignant human plasma cells. The initial monoclonal antibodies were created by fusing spleen cells from an immunized mouse with human or mouse myeloma cells (malignant self-perpetuating antibody producing cells), and selecting out and cloning the hybrid cells (hybridomas) that produced the desired antibody reactivity. These initial monoclonal products were mouse antibodies and were very valuable in laboratory and animal research and diagnostic assays, but were problematic as therapeutic agents because of immune reactions to the foreign mouse protein. Subsequently, production of chimeric mouse-human monoclonal antibodies and means of further “humanizing” them and producing fully human recombinant monoclonal antibodies were developed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/monoclonalab-220520073748-aca9db26-thumbnail.jpg?width=120&height=120&fit=bounds" /> Monoclonal antibodies are antibodies that have a high degree of specificity (mono-specificity) for an antigen or epitope. Monoclonal antibodies are typically derived from a clonal expansion of antibody producing malignant human plasma cells. The initial monoclonal antibodies were created by fusing spleen cells from an immunized mouse with human or mouse myeloma cells (malignant self-perpetuating antibody producing cells), and selecting out and cloning the hybrid cells (hybridomas) that produced the desired antibody reactivity. These initial monoclonal products were mouse antibodies and were very valuable in laboratory and animal research and diagnostic assays, but were problematic as therapeutic agents because of immune reactions to the foreign mouse protein. Subsequently, production of chimeric mouse-human monoclonal antibodies and means of further “humanizing” them and producing fully human recombinant monoclonal antibodies were developed.

Monoclonal Antibody Process.pdf from D.R. Chandravanshi

]]> 79 0 https://cdn.slidesharecdn.com/ss_thumbnails/monoclonalab-220520073748-aca9db26-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 National Health Programs, Objectives, Fucntions /slideshow/national-health-programs-objectives-fucntions/251229736 nationalhealthprograms-220223083914
Program among these measures are the NATIONAL HEALTH PROGRAMS, which have been launched by the central government of control/ eradication of communicable diseases, improvement of environmental sanitation, raising the standard of nutrition, control of population and improving rural health. Introduction]]>
Program among these measures are the NATIONAL HEALTH PROGRAMS, which have been launched by the central government of control/ eradication of communicable diseases, improvement of environmental sanitation, raising the standard of nutrition, control of population and improving rural health. Introduction]]> Wed, 23 Feb 2022 08:39:13 GMT /slideshow/national-health-programs-objectives-fucntions/251229736 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) National Health Programs, Objectives, Fucntions DauRamChandravanshi1 Program among these measures are the NATIONAL HEALTH PROGRAMS, which have been launched by the central government of control/ eradication of communicable diseases, improvement of environmental sanitation, raising the standard of nutrition, control of population and improving rural health. Introduction <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nationalhealthprograms-220223083914-thumbnail.jpg?width=120&height=120&fit=bounds" /> Program among these measures are the NATIONAL HEALTH PROGRAMS, which have been launched by the central government of control/ eradication of communicable diseases, improvement of environmental sanitation, raising the standard of nutrition, control of population and improving rural health. Introduction

National Health Programs, Objectives, Fucntions from D.R. Chandravanshi

]]> 3636 0 https://cdn.slidesharecdn.com/ss_thumbnails/nationalhealthprograms-220223083914-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 EU(European Union) and ICH Guidelines /slideshow/eueuropean-union-and-ich-guidelines/251229621 euandichguidelines-220223082434
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation.]]>
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation.]]> Wed, 23 Feb 2022 08:24:33 GMT /slideshow/eueuropean-union-and-ich-guidelines/251229621 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) EU(European Union) and ICH Guidelines DauRamChandravanshi1 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/euandichguidelines-220223082434-thumbnail.jpg?width=120&height=120&fit=bounds" /> The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation.

EU(European Union) and ICH Guidelines from D.R. Chandravanshi

]]> 8900 0 https://cdn.slidesharecdn.com/ss_thumbnails/euandichguidelines-220223082434-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Forms of business organization, DSBM D.Pharma 2nd year /slideshow/forms-of-business-organization-dsbm-dpharma-2nd-year-251029776/251029776 formsofbusinessorganization-220121044926
The legal entity can be in any form of a business organization. The various forms of organization are as follows: 1) Sole proprietorship 2) Partnership 3) Co-operative Society 4) Joint stock company (Private and Public) These are explained in brief as follows:-3.1 OBJECTIVES At the end of this lesson you will be able to know z Various forms of organization z Its formation & features z Merits & Demerits]]>
The legal entity can be in any form of a business organization. The various forms of organization are as follows: 1) Sole proprietorship 2) Partnership 3) Co-operative Society 4) Joint stock company (Private and Public) These are explained in brief as follows:-3.1 OBJECTIVES At the end of this lesson you will be able to know z Various forms of organization z Its formation & features z Merits & Demerits]]> Fri, 21 Jan 2022 04:49:26 GMT /slideshow/forms-of-business-organization-dsbm-dpharma-2nd-year-251029776/251029776 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Forms of business organization, DSBM D.Pharma 2nd year DauRamChandravanshi1 The legal entity can be in any form of a business organization. The various forms of organization are as follows: 1) Sole proprietorship 2) Partnership 3) Co-operative Society 4) Joint stock company (Private and Public) These are explained in brief as follows:-3.1 OBJECTIVES At the end of this lesson you will be able to know z Various forms of organization z Its formation & features z Merits & Demerits <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/formsofbusinessorganization-220121044926-thumbnail.jpg?width=120&height=120&fit=bounds" /> The legal entity can be in any form of a business organization. The various forms of organization are as follows: 1) Sole proprietorship 2) Partnership 3) Co-operative Society 4) Joint stock company (Private and Public) These are explained in brief as follows:-3.1 OBJECTIVES At the end of this lesson you will be able to know z Various forms of organization z Its formation & features z Merits & Demerits

Forms of business organization, DSBM D.Pharma 2nd year from D.R. Chandravanshi

]]> 1259 0 https://cdn.slidesharecdn.com/ss_thumbnails/formsofbusinessorganization-220121044926-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Psoriasis: Natural Product and Phytomedicine /slideshow/psoriasis-natural-product-and-phytomedicine-240843687/240843687 psoriasisppt-210102120836
Psoriasis is an autoimmune condition that affects skin. It is characterized by changes in the skin that include hyperkeratosis, parakeratosis, and akantosis. They are attributed to an increased mitosis rate in the basal region of the epidermis, as well as disorders of maturing and differentiating keratinocytes. These changes in the dermis and epidermis cause the typical desquamation of the stratum corneum observed in psoriasis. The psoriatic lesions indicate an inflammatory reaction caused by the secretion of pro-inflammatory cytokines from macrophages, lymphocytes, and neutrophils. These cytokines may stimulate the inflammatory response via the lipoxygenase and the cyclooxygenase (COX) pathways. The red, scaling psoriatic plaques often itch and burn. People with psoriasis may suffer discomfort, including pain and itching and emotional distress Psoriasis affects 1% to 2% of the population.]]>
Psoriasis is an autoimmune condition that affects skin. It is characterized by changes in the skin that include hyperkeratosis, parakeratosis, and akantosis. They are attributed to an increased mitosis rate in the basal region of the epidermis, as well as disorders of maturing and differentiating keratinocytes. These changes in the dermis and epidermis cause the typical desquamation of the stratum corneum observed in psoriasis. The psoriatic lesions indicate an inflammatory reaction caused by the secretion of pro-inflammatory cytokines from macrophages, lymphocytes, and neutrophils. These cytokines may stimulate the inflammatory response via the lipoxygenase and the cyclooxygenase (COX) pathways. The red, scaling psoriatic plaques often itch and burn. People with psoriasis may suffer discomfort, including pain and itching and emotional distress Psoriasis affects 1% to 2% of the population.]]> Sat, 02 Jan 2021 12:08:36 GMT /slideshow/psoriasis-natural-product-and-phytomedicine-240843687/240843687 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Psoriasis: Natural Product and Phytomedicine DauRamChandravanshi1 Psoriasis is an autoimmune condition that affects skin. It is characterized by changes in the skin that include hyperkeratosis, parakeratosis, and akantosis. They are attributed to an increased mitosis rate in the basal region of the epidermis, as well as disorders of maturing and differentiating keratinocytes. These changes in the dermis and epidermis cause the typical desquamation of the stratum corneum observed in psoriasis. The psoriatic lesions indicate an inflammatory reaction caused by the secretion of pro-inflammatory cytokines from macrophages, lymphocytes, and neutrophils. These cytokines may stimulate the inflammatory response via the lipoxygenase and the cyclooxygenase (COX) pathways. The red, scaling psoriatic plaques often itch and burn. People with psoriasis may suffer discomfort, including pain and itching and emotional distress Psoriasis affects 1% to 2% of the population. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/psoriasisppt-210102120836-thumbnail.jpg?width=120&height=120&fit=bounds" /> Psoriasis is an autoimmune condition that affects skin. It is characterized by changes in the skin that include hyperkeratosis, parakeratosis, and akantosis. They are attributed to an increased mitosis rate in the basal region of the epidermis, as well as disorders of maturing and differentiating keratinocytes. These changes in the dermis and epidermis cause the typical desquamation of the stratum corneum observed in psoriasis. The psoriatic lesions indicate an inflammatory reaction caused by the secretion of pro-inflammatory cytokines from macrophages, lymphocytes, and neutrophils. These cytokines may stimulate the inflammatory response via the lipoxygenase and the cyclooxygenase (COX) pathways. The red, scaling psoriatic plaques often itch and burn. People with psoriasis may suffer discomfort, including pain and itching and emotional distress Psoriasis affects 1% to 2% of the population.

Psoriasis: Natural Product and Phytomedicine from D.R. Chandravanshi

]]> 806 0 https://cdn.slidesharecdn.com/ss_thumbnails/psoriasisppt-210102120836-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Omega 3 fatty acids d rc /slideshow/omega-3-fatty-acids-d-rc/238443514 omega-3fattyacidsdrc-200910115810
Omega−3 fatty acids, also called Omega-3 oils, ω−3 fatty acids or n−3 fatty acids, are polyunsaturated fatty acids (PUFAs) characterized by the presence of a double bond three atoms away from the terminal methyl group in their chemical structure. They are widely distributed in nature, being important constituents of animal lipid metabolism, and they play an important role in the human diet and in human physiology. /DauRamChandravanshi1]]>
Omega−3 fatty acids, also called Omega-3 oils, ω−3 fatty acids or n−3 fatty acids, are polyunsaturated fatty acids (PUFAs) characterized by the presence of a double bond three atoms away from the terminal methyl group in their chemical structure. They are widely distributed in nature, being important constituents of animal lipid metabolism, and they play an important role in the human diet and in human physiology. /DauRamChandravanshi1]]> Thu, 10 Sep 2020 11:58:10 GMT /slideshow/omega-3-fatty-acids-d-rc/238443514 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Omega 3 fatty acids d rc DauRamChandravanshi1 Omega−3 fatty acids, also called Omega-3 oils, ω−3 fatty acids or n−3 fatty acids, are polyunsaturated fatty acids (PUFAs) characterized by the presence of a double bond three atoms away from the terminal methyl group in their chemical structure. They are widely distributed in nature, being important constituents of animal lipid metabolism, and they play an important role in the human diet and in human physiology. /DauRamChandravanshi1 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/omega-3fattyacidsdrc-200910115810-thumbnail.jpg?width=120&height=120&fit=bounds" /> Omega−3 fatty acids, also called Omega-3 oils, ω−3 fatty acids or n−3 fatty acids, are polyunsaturated fatty acids (PUFAs) characterized by the presence of a double bond three atoms away from the terminal methyl group in their chemical structure. They are widely distributed in nature, being important constituents of animal lipid metabolism, and they play an important role in the human diet and in human physiology. /DauRamChandravanshi1

Omega 3 fatty acids d rc from D.R. Chandravanshi

]]> 3865 0 https://cdn.slidesharecdn.com/ss_thumbnails/omega-3fattyacidsdrc-200910115810-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Pilot Plant Techniques for SOLID dosage forms /slideshow/pilot-plant-techniques-for-solid-dosage-forms/232987198 pilotplantforsoliddosageforms-200501063118
Pilot Plant:- “Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”. Scale-up:- “The art of designing of prototype using the data obtained from the pilot plant model”]]>
Pilot Plant:- “Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”. Scale-up:- “The art of designing of prototype using the data obtained from the pilot plant model”]]> Fri, 01 May 2020 06:31:18 GMT /slideshow/pilot-plant-techniques-for-solid-dosage-forms/232987198 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Pilot Plant Techniques for SOLID dosage forms DauRamChandravanshi1 Pilot Plant:- “Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”. Scale-up:- “The art of designing of prototype using the data obtained from the pilot plant model” <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pilotplantforsoliddosageforms-200501063118-thumbnail.jpg?width=120&height=120&fit=bounds" /> Pilot Plant:- “Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”. Scale-up:- “The art of designing of prototype using the data obtained from the pilot plant model”

Pilot Plant Techniques for SOLID dosage forms from D.R. Chandravanshi

]]> 27162 0 https://cdn.slidesharecdn.com/ss_thumbnails/pilotplantforsoliddosageforms-200501063118-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Optimum Performance Laminar Chromatography (OPLC) /slideshow/optimum-performance-laminar-chromatography-oplc/194052087 oplc-191115203922
Optimum performance laminar chromatography (OPLC) is a pumped flow chromatography techniques that combine the user – friendly interface of HPLC with the capacity of flash chromatography and multidimensionally of TLC . Optimum performance laminar chromatography (OPLC ) , in a contrast , is a pumped flow chromatography system that uses a planar 2D column format . The multidimensionally capacity of OPLC is not limited to the separation technique alone , but also to the multitude of sample application and detection methods that are available . ]]>
Optimum performance laminar chromatography (OPLC) is a pumped flow chromatography techniques that combine the user – friendly interface of HPLC with the capacity of flash chromatography and multidimensionally of TLC . Optimum performance laminar chromatography (OPLC ) , in a contrast , is a pumped flow chromatography system that uses a planar 2D column format . The multidimensionally capacity of OPLC is not limited to the separation technique alone , but also to the multitude of sample application and detection methods that are available . ]]> Fri, 15 Nov 2019 20:39:22 GMT /slideshow/optimum-performance-laminar-chromatography-oplc/194052087 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Optimum Performance Laminar Chromatography (OPLC) DauRamChandravanshi1 Optimum performance laminar chromatography (OPLC) is a pumped flow chromatography techniques that combine the user – friendly interface of HPLC with the capacity of flash chromatography and multidimensionally of TLC . Optimum performance laminar chromatography (OPLC ) , in a contrast , is a pumped flow chromatography system that uses a planar 2D column format . The multidimensionally capacity of OPLC is not limited to the separation technique alone , but also to the multitude of sample application and detection methods that are available . <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/oplc-191115203922-thumbnail.jpg?width=120&height=120&fit=bounds" /> Optimum performance laminar chromatography (OPLC) is a pumped flow chromatography techniques that combine the user – friendly interface of HPLC with the capacity of flash chromatography and multidimensionally of TLC . Optimum performance laminar chromatography (OPLC ) , in a contrast , is a pumped flow chromatography system that uses a planar 2D column format . The multidimensionally capacity of OPLC is not limited to the separation technique alone , but also to the multitude of sample application and detection methods that are available .

Optimum Performance Laminar Chromatography (OPLC) from D.R. Chandravanshi

]]> 3765 1 https://cdn.slidesharecdn.com/ss_thumbnails/oplc-191115203922-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE /slideshow/synthetic-peptide-vaccines-and-recombinant-antigen-vaccine/194052075 newmicrosoftofficepowerpointpresentation2-191115203918
What is a Vaccine? A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response. 1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources). 2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams. 3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae. Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines. ]]>
What is a Vaccine? A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response. 1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources). 2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams. 3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae. Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines. ]]> Fri, 15 Nov 2019 20:39:18 GMT /slideshow/synthetic-peptide-vaccines-and-recombinant-antigen-vaccine/194052075 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE DauRamChandravanshi1 What is a Vaccine? A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response. 1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources). 2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams. 3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae. Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/newmicrosoftofficepowerpointpresentation2-191115203918-thumbnail.jpg?width=120&height=120&fit=bounds" /> What is a Vaccine? A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response. 1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources). 2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams. 3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae. Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines.

SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE from D.R. Chandravanshi

]]> 9263 1 https://cdn.slidesharecdn.com/ss_thumbnails/newmicrosoftofficepowerpointpresentation2-191115203918-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 New generation vaccines production /slideshow/new-generation-vaccines-production/194052020 newgenerationvaccines-191115203857
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. HISTORY OF VACCINES- EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox. A vaccine for RABIES is developed by LOUIS PASTEUR . Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887. The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK. The whole cell PERTUSIS vaccines are developed in 1914. A TETANUS vaccine is developed in 1927.]]>
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. HISTORY OF VACCINES- EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox. A vaccine for RABIES is developed by LOUIS PASTEUR . Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887. The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK. The whole cell PERTUSIS vaccines are developed in 1914. A TETANUS vaccine is developed in 1927.]]> Fri, 15 Nov 2019 20:38:56 GMT /slideshow/new-generation-vaccines-production/194052020 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) New generation vaccines production DauRamChandravanshi1 vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. HISTORY OF VACCINES- EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox. A vaccine for RABIES is developed by LOUIS PASTEUR . Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887. The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK. The whole cell PERTUSIS vaccines are developed in 1914. A TETANUS vaccine is developed in 1927. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/newgenerationvaccines-191115203857-thumbnail.jpg?width=120&height=120&fit=bounds" /> vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. HISTORY OF VACCINES- EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox. A vaccine for RABIES is developed by LOUIS PASTEUR . Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887. The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK. The whole cell PERTUSIS vaccines are developed in 1914. A TETANUS vaccine is developed in 1927.

New generation vaccines production from D.R. Chandravanshi

]]> 8344 0 https://cdn.slidesharecdn.com/ss_thumbnails/newgenerationvaccines-191115203857-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Monoclonal Antibody and Hybridoma technology /slideshow/monoclonal-antibody-and-hybridoma-technology/194052004 monoclonal-191115203853
Immunity It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens. Immune system It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system. In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies. antibody Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens. monoclonal antibodies Antibodies that are made by identical immune cells that are clones of a unique parent cell. polyclonal antibodies A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen.]]>
Immunity It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens. Immune system It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system. In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies. antibody Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens. monoclonal antibodies Antibodies that are made by identical immune cells that are clones of a unique parent cell. polyclonal antibodies A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen.]]> Fri, 15 Nov 2019 20:38:53 GMT /slideshow/monoclonal-antibody-and-hybridoma-technology/194052004 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Monoclonal Antibody and Hybridoma technology DauRamChandravanshi1 Immunity It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens. Immune system It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system. In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies. antibody Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens. monoclonal antibodies Antibodies that are made by identical immune cells that are clones of a unique parent cell. polyclonal antibodies A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/monoclonal-191115203853-thumbnail.jpg?width=120&height=120&fit=bounds" /> Immunity It can be defined as the resistance to disease, specifically to infectious disease or pathogens. The term “immune” is derived from the Latin word “immunis” that is exempt from charges. In medical term, it refers to the being protected from infectious pathogens. Immune system It is adaptive defense system which is able to generate a variety of cell and molecules capable of specifically recognizing and eliminating a variety of limitless foreign invaders into the system. In 1975 Georges Kohler and Milstein succeeded in making fusions of myeloma cell lines with B cells to create hybridomas that could produce antibodies. antibody Also known as immunoglobulin is a large, Y shaped glycoprotein produced mainly by plasma cells that is used by the immune system to neutralize pathogens. monoclonal antibodies Antibodies that are made by identical immune cells that are clones of a unique parent cell. polyclonal antibodies A polyclonal antibodies represents a collection of antibodies from different B cells that recognize multiple epitopes on the same antigen.

Monoclonal Antibody and Hybridoma technology from D.R. Chandravanshi

]]> 820 0 https://cdn.slidesharecdn.com/ss_thumbnails/monoclonal-191115203853-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Scanning Electron Microscope (SEM) /slideshow/scanning-electron-microscope-sem-194051983/194051983 manoranjan-191115203845
A scanning electron microscope is a type of electron microscope that produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing various signals that contain information about the sample's surface topography and composition. SEMs can magnify an object from about 10 times up to 300,000 times. A scale bar is often provided on an SEM image. From this the actual size of structures in the image can be calculated. ]]>
A scanning electron microscope is a type of electron microscope that produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing various signals that contain information about the sample's surface topography and composition. SEMs can magnify an object from about 10 times up to 300,000 times. A scale bar is often provided on an SEM image. From this the actual size of structures in the image can be calculated. ]]> Fri, 15 Nov 2019 20:38:45 GMT /slideshow/scanning-electron-microscope-sem-194051983/194051983 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Scanning Electron Microscope (SEM) DauRamChandravanshi1 A scanning electron microscope is a type of electron microscope that produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing various signals that contain information about the sample's surface topography and composition. SEMs can magnify an object from about 10 times up to 300,000 times. A scale bar is often provided on an SEM image. From this the actual size of structures in the image can be calculated. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/manoranjan-191115203845-thumbnail.jpg?width=120&height=120&fit=bounds" /> A scanning electron microscope is a type of electron microscope that produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing various signals that contain information about the sample's surface topography and composition. SEMs can magnify an object from about 10 times up to 300,000 times. A scale bar is often provided on an SEM image. From this the actual size of structures in the image can be calculated.

Scanning Electron Microscope (SEM) from D.R. Chandravanshi

]]> 21986 1 https://cdn.slidesharecdn.com/ss_thumbnails/manoranjan-191115203845-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Gas chromatography mass spectrometry (GC-MS) /slideshow/gas-chromatography-mass-spectrometry-gcms/194048604 gaschromatography-massspectrometrygc-ms-191115202105
Gas chromatography-mass spectrometry (GC-MS) is the synergistic combination of two analytical method to separate and identify different substances within a test sample. Gas chromatography separates the components of a mixture in time. Mass spectrometer provides information that aids in the identification and structural elucidation of each component.]]>
Gas chromatography-mass spectrometry (GC-MS) is the synergistic combination of two analytical method to separate and identify different substances within a test sample. Gas chromatography separates the components of a mixture in time. Mass spectrometer provides information that aids in the identification and structural elucidation of each component.]]> Fri, 15 Nov 2019 20:21:05 GMT /slideshow/gas-chromatography-mass-spectrometry-gcms/194048604 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Gas chromatography mass spectrometry (GC-MS) DauRamChandravanshi1 Gas chromatography-mass spectrometry (GC-MS) is the synergistic combination of two analytical method to separate and identify different substances within a test sample. Gas chromatography separates the components of a mixture in time. Mass spectrometer provides information that aids in the identification and structural elucidation of each component. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/gaschromatography-massspectrometrygc-ms-191115202105-thumbnail.jpg?width=120&height=120&fit=bounds" /> Gas chromatography-mass spectrometry (GC-MS) is the synergistic combination of two analytical method to separate and identify different substances within a test sample. Gas chromatography separates the components of a mixture in time. Mass spectrometer provides information that aids in the identification and structural elucidation of each component.

Gas chromatography mass spectrometry (GC-MS) from D.R. Chandravanshi

]]> 87226 4 https://cdn.slidesharecdn.com/ss_thumbnails/gaschromatography-massspectrometrygc-ms-191115202105-thumbnail.jpg?width=120&height=120&fit=bounds presentation White http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Formulation of parenteral products /slideshow/formulation-of-parenteral-products/194048581 formulationofparenterals-2neetesh-191115202059
These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient. These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient.]]>
These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient. These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient.]]> Fri, 15 Nov 2019 20:20:59 GMT /slideshow/formulation-of-parenteral-products/194048581 DauRamChandravanshi1@slideshare.net(DauRamChandravanshi1) Formulation of parenteral products DauRamChandravanshi1 These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient. These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/formulationofparenterals-2neetesh-191115202059-thumbnail.jpg?width=120&height=120&fit=bounds" /> These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient. These are the sterile preparation intended to administered other than intestinal route to bypass first pass metabolism and directly goes to systemic circulation. These preparation give quick onset of action and site specific activity. Suitable for drugs which are inactive in GIT environment. Can be given unconscious or vomiting or diarrheal patient.

Formulation of parenteral products from D.R. Chandravanshi

]]> 4709 0 https://cdn.slidesharecdn.com/ss_thumbnails/formulationofparenterals-2neetesh-191115202059-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-DauRamChandravanshi1-48x48.jpg?cb=1729446349 Research Scholar Presently Pursuing Ph.D., Previously worked as Assistant Professor at SOP Mangalayatan University and GGV Bilaspur. www.linkedin.com/in/dau-ram-chandravanshi-306386112/ https://cdn.slidesharecdn.com/ss_thumbnails/unit-vradiopharmaceuticals-241210053442-11920643-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/pharmaceutical-inorganic-chemistry-unit-v-radiopharmaceuticals/273954137 Pharmaceutical Inorgan... https://cdn.slidesharecdn.com/ss_thumbnails/gastrointestinalagents-241020015158-93ac85e5-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/pharma-inorganic-chemistry-gastrointestinal-agents-pptx/272564363 Pharma. Inorganic Chem... https://cdn.slidesharecdn.com/ss_thumbnails/classtest-230522021733-33fdd469-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/questions-of-central-nervous-system/257947387 Questions of Central N...